Agile Therapeutics (NASDAQ:AGRX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Agile Therapeutics and Rigel Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Agile Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
| Rigel Pharmaceuticals | 0 | 1 | 3 | 0 | 2.75 |
Agile Therapeutics presently has a consensus target price of $8.25, indicating a potential upside of 334.21%. Rigel Pharmaceuticals has a consensus target price of $8.3333, indicating a potential upside of 123.41%. Given Agile Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Agile Therapeutics is more favorable than Rigel Pharmaceuticals.
Risk & Volatility
Agile Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Insider and Institutional Ownership
44.4% of Agile Therapeutics shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 4.4% of Agile Therapeutics shares are held by insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Agile Therapeutics and Rigel Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Agile Therapeutics | N/A | N/A | $-18,610,000.00 | ($0.38) | -5.00 |
| Rigel Pharmaceuticals | $59.29 million | 10.70 | $-66,890,000.00 | ($0.40) | -9.33 |
Agile Therapeutics has higher earnings, but lower revenue than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Agile Therapeutics and Rigel Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Agile Therapeutics | N/A | -56.84% | -45.89% |
| Rigel Pharmaceuticals | -26.25% | -44.96% | -20.08% |
Summary
Agile Therapeutics beats Rigel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
